The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies

CAR T cell therapy has revolutionized the cancer therapy. However, for an effective therapy, selecting an ideal target antigen on the cancer cell is a prerequisite. The purpose of this review is to provide an overview of all the possible cancer antigens in hematological malignancies that can be targeted by CAR T cells.

Owing to the fast-paced research in the field of CAR T cell therapy, a plethora of surface antigens on the cancer cell have been identified against which CAR T cells have been successfully made. Over the years, CAR T cells targeting CD19 and BCMA have been approved by the FDA, and many others have shown tremendous efficacy to combat cancer.

This review gives an overview of all the cancer antigens that have been targeted by CAR T cell therapy.